Introduction {#s0001}
============

Tofacitinib is a novel, potent and selective inhibitor of the JAK family of kinases and is most specific for JAK3, followed by JAK1 and then JAK2 (Sharma et al. [@CIT0034]). Tofacitinib has been approved in many countries for the treatment of moderate to severe rheumatoid arthritis (Fleischmann et al. [@CIT0011]; Fleischmann [@CIT0009], [@CIT0010]; Gupta et al. [@CIT0012]). The metabolism of tofacitinib is mainly mediated by CYP450 3A4 (53%), and a small portion of it is mediated by CYP2C19 (17%) (Fleischmann [@CIT0010]). It has previously been reported (Dowty et al. [@CIT0008]; Hodge et al. [@CIT0016]) that when coadministered with potent CYP3A4 inhibitors such as ketoconazole or fluconazole, the systemic exposure of tofacitinib increased significantly. When coadministered with potent CYP3A4 inducers such as rifampin, the systemic exposure of tofacitinib decreased. Considering the pharmacokinetic characteristics of tofacitinib, we hypothesize that when tofacitinib is coadministered with food or herbs that can alter the effects of CYP3A4, the metabolism of tofacitinib *in vivo* may be altered.

Flavonoids are important components of plant secondary metabolites and are abundant in vegetables, fruits and beverages. Flavonoids play important roles in plant cell cycle inhibition, nitrogen fixation and UV filtration and act as chemical signals in some plants. In addition, certain substances in flavonoids mainly affect the healthy growth of plants by inhibiting spore colonization (Joshi et al. [@CIT0019]). Previous studies have identified the physicochemical properties, pharmacokinetic parameters and biological effects of flavonoids (Zhang et al. [@CIT0040]; Xu et al. [@CIT0039]). Due to the wide variety of flavonoids and their special pharmacological properties, flavonoids have multiple therapeutic effects in many diseases. Naringenin is a representative flavonoid that mainly exists in orange, grapefruit, tomato and lemon peel. It has antioxidant, antiinflammatory, antiallergic, antihepatotoxicity, anticancer and antithrombosis effects and plays an important role in the treatment of rheumatoid arthritis (Alam et al. [@CIT0001]; Li et al. [@CIT0020]; Jia et al. [@CIT0018]; Rengasamy et al. [@CIT0030]; Salehi et al. [@CIT0031]). In China, naringenin is widely used in medicine, food and other fields. Therefore, the study of the role of naringenin has great clinical value. Several previous experiments (Burkina et al. [@CIT0005]; Liu J et al. [@CIT0023]) have indicated that naringenin is an inhibitor of CYP3A4. Drug--drug interactions (DDIs), which can produce unrelated, synergistic, additive and antagonistic results, are increasingly recognized as important clinical events (Zhang et al. [@CIT0041]; Zhou et al. [@CIT0044]).

In China, it is common to use herbs to treat some diseases. However, people are becoming increasingly aware of the importance of DDIs. In the last few years, several studies on the interactions between flavonoids and drugs have been reported (Seden et al. [@CIT0032]; Alnaqeeb et al. [@CIT0002]; Zhao et al. [@CIT0043]). Given the potential antiinflammatory effects of naringenin, it is often used together with tofacitinib for the treatment of rheumatoid arthritis in Chinese clinics (Gupta et al. [@CIT0013]; Ananth et al. [@CIT0003]; Banerjee et al. [@CIT0004]). However, the herb--drug interaction between naringenin and tofacitinib is still unknown. The purpose of this experiment was to investigate the effects of naringenin on the pharmacokinetics of tofacitinib in Sprague-Dawley rats. The pharmacokinetic parameters of tofacitinib in rats with or without naringenin pre-treatment were analysed using a sensitive and reliable UPLC/MS--MS system.

Materials and methods {#s0002}
=====================

Chemicals and reagents {#s0003}
----------------------

Tofacitinib (purity \> 98%) and naringenin (purity \> 98%) were both purchased from the Beijing Sunflower and Technology Development Co. Ltd. (Beijing, China). Acetonitrile and methanol were obtained from Fisher Scientific Co. (Fair Lawn, NJ). Formic acid was procured by Sigma-Aldrich (St. Louis, MO). Ultrapure water was obtained from a Milli-Q water purification system (Millipore, Billerica, MA). All other chemicals were of analytical grade or better.

Animal experiments {#s0004}
------------------

Twelve female Sprague-Dawley rats weighing 230--250 g were provided by the experimental animal centre of Wenzhou Medical University (Wenzhou, China). The rats were randomly divided into two groups of six animals each. Rats were bred in a breeding room at 25 °C with 60 ± 5% humidity and a 12-h dark--light cycle. Enough tap water and normal chow were provided *ad libitum*. The Sprague-Dawley rats were placed under the above conditions for one week before initiating the animal experiment. This experiment was approved by Laboratory Animal Ethics Committee of Wenzhou Medical University.

Pharmacokinetic experiment {#s0005}
--------------------------

To investigate the effects of naringenin on the pharmacokinetics of tofacitinib, the Sprague-Dawley female rats were divided into two groups. The test group was pre-treated with naringenin by oral gavage at a dose of 150 mg/kg/day (dissolved in CMC-Na solution) for two weeks before the administration of tofacitinib. The control group also received equal amounts of vehicle (CMC-Na solution). Tofacitinib was dissolved in dimethyl sulphoxide (DMSO) and was then diluted with polyethylene glycol 200 so that DMSO accounted for 5% of the total volume. Each group of rats was given an oral gavage at a dose of 5 mg/kg of tofacitinib, and then blood was taken from the rat's tail vein for analysis at 0.083, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 and 24 h.

Instruments and conditions {#s0006}
--------------------------

The plasma sample analysis was performed on a UPLC--MS/MS system with an ACQUITY I Class UPLC and a XEVO TQD triple quadrupole mass spectrometer (Waters Corp., Milford, MA). The UPLC system consists of a Binary Solvent Manager (BSM) and a Sample Manager with Flow-Through Needle (SM-FTN). The chromatographic analysis of tofacitinib was performed on a CORTECS C18 column (2.1 × 50 mm, 1.6 µm) maintained at 40 °C. The initial mobile phase consisted of 0.1% formic acid and acetonitrile with gradient elution at a flow rate of 0.4 mL/min. Elution was in a linear gradient, where the acetonitrile increased from 10 to 30% (0--1 min), rapidly rose from 30 to 95% (1--2 min), was maintained at 95% (2--2.5 min), then decreased to 10% (2.5--2.6 min). The total time required for analysis was 3 min. The sample manager underwent a strong wash (methanol water, 50/50, v/v) and a weak wash (methanol water, 10/90, v/v) after each injection.

The mass scan mode was the positive MRM mode. The precursor ion and product ion were *m/z* 313.18 → 149.03 for tofacitinib and *m/z* 492.06 → 354.55 for poziotinib (internal standard), respectively ([Figure 1](#F0001){ref-type="fig"}). The optimal MS parameters were defined as follows: the cone voltages were set at 40 V and 30 V for tofacitinib and IS; the collision energies were set at 30 V and 28 V for tofacitinib and IS. Masslynx 4.1 software (Waters Corp., Milford, MA) was used for data acquisition and instrument control.

![The chemical structures and mass spectra of tofacitinib (A) and IS (B).](IPHB_A_1738504_F0001_C){#F0001}

Plasma sample preparation {#s0007}
-------------------------

A 50 μL aliquot of the blood sample was placed in a 1.5 mL microcentrifuge tube according to the time point, and to that 20 μL of IS and 100 μL of acetonitrile were added. The mixture was vortexed for 30 s and then centrifuged at 13,000 rpm for 5 min. Subsequently, the supernatants were taken each in a separate sample bottle. Supernatant (5 μL) was analysed using a sensitive and reliable LC--MS/MS method.

Method validation {#s0008}
-----------------

The validation procedures for selectivity, linearity, accuracy, precision, recovery and stability referred to the European Medicines Agency Guidelines and US-FDA Bioanalytical Method Validation Guidance (Shah et al. [@CIT0033]; Ma et al. [@CIT0025]; Wen et al. [@CIT0037]; Zhou et al. [@CIT0045]; Wang S et al. [@CIT0036]; Wang X et al. [@CIT0035]; Lowes and Ackermann [@CIT0024]).

Specificity {#s0009}
-----------

Specificity was investigated by comparing the following three groups. According to the same procedure of 'plasma sample preparation' above, 10 µL aliquots of supernatant were extracted from six blank rat plasmas for analysis. Next, the tofacitinib standard solution (1 ng/mL) and IS (500 ng/mL) were added to the plasma to obtain the corresponding data. Finally, after 3 h of oral administration of tofacitinib in rats, the six rat plasma samples were analysed by the same procedure as above.

Linearity and sensitivity {#s0010}
-------------------------

To determine the calibration curves, nine concentrations (1, 2.5, 5, 10, 25, 50, 100, 250 and 500 ng/mL) of standard plasma samples were analysed in triplicate. The tofacitinib concentration (ng/mL) was plotted on the abscissa (*X*), and the peak area ratio of tofacitinib and IS was plotted on the ordinate (*Y*). The data were subjected to a regression operation, and the obtained linear regression equation was the calibration curve. The lower limit of quantification (LLOQ) was determined as the concentration of the analyte with a signal-to-noise ratio of 10.

Precision and accuracy {#s0011}
----------------------

According to the linearity and sensitivity, the quality control samples of the low, medium and high concentrations of tofacitinib (2, 20 and 200 ng/mL) were obtained. Six replicate analyses were performed on each sample for three consecutive days. The concentration of QC samples was calculated using the accompanying standard curve. The inter- and intra-day precision (express by RSD) and accuracy (express by RE) were obtained by analysis of variance and comparison with the configured concentrations, respectively.

Extraction recovery and matrix effects {#s0012}
--------------------------------------

The extraction recovery was evaluated by calculating the ratio of QC samples obtained against those originally spiked in the blank plasma. The matrix effect was determined by comparing the solution spiked with the blank processed matrix with the solution at three different QC concentrations. The above two steps were repeated six times.

Stability {#s0013}
---------

The stability index should evaluate the stability of the test object at each step of the method, which generally includes short-term, long-term, freeze--thaw and autosampler stabilities. The short-term, autosampler and long-term stabilities were evaluated by measuring QC samples at room temperature for 6 h, 12 h and at −80 °C for 14 days, respectively. The freeze--thaw stability was measured by three freeze--thaw cycles on consecutive days.

Statistical analysis {#s0014}
--------------------

The pharmacokinetic parameters, including maximal plasma concentration (*C*~max~), the time to peak plasma concentration (*T*~max~), the area under the plasma concentration--time curve (AUC), the elimination half-life (*t*~1/2~) and the mean residence time (MRT), were analysed using DAS (Drug and Statistics) software (Version 3.2.8, The People's Hospital of Lishui, Lishui, China).

All the pharmacokinetic parameters are expressed as the mean ± SD. Statistical analyses of main pharmacokinetic parameters were analysed for significance using the independent sample Student's *t-*test. Values of *p* \< 0.05 were considered to be statistically significant.

Results {#s0015}
=======

Method validation {#s0016}
-----------------

As shown in [Figure 2](#F0002){ref-type="fig"}, the RTs of tofacitinib and IS were 0.68 and 1.52 min, respectively. Compared with blank plasma, it could be concluded that endogenous substances and metabolites in plasma did not interfere with the determination (tofacitinib and IS).

![The MRM chromatograms of tofacitinib and IS. (1) Blank plasma sample, (2) blank plasma sample with tofacitinib (LLOQ) and IS and (3) plasma sample after 3 hours of oral administration of tofacitinib.](IPHB_A_1738504_F0002_C){#F0002}

Through the above data, a regression calculation could be used to obtain the calibration curve. The correlation coefficient between the regression equation and the standard curve was *y* = 0.0143035*x* + 0.146099 (*r* = 0.995516). The results showed that the concentration of tofacitinib in plasma was in the range of 1.0--500.0 ng/mL, and the linear relationship was good. The LLOQ was set at 0.1 ng/mL for tofacitinib in rat plasma samples.

According to the QC sample, the accuracy and precision of the experiment were calculated. The experimental results of the QC sample of the tofacitinib were in line with the relevant requirements for biological sample determination. The specific data are shown in [Table 1](#t0001){ref-type="table"}. The intra- and inter-day precision values (RSD) of QC samples with all different concentration levels were less than 15%. The intra- and inter-day accuracies (RE) were in the range of −10% to 10%.

###### 

Inter- and intra-day precision, accuracy, recovery and matrix of tofacitinib in rat plasma (*n* = 6, mean ± SD).

  Analyte       Nominal concentration (ng/mL)   Intra-day   Inter-day   Recovery (%)   Matrix (%)           
  ------------- ------------------------------- ----------- ----------- -------------- ------------ ------- ---
  Tofacitinib   1                               14.56       106.6       8.11           103.87                
  2             7.21                            109.45      13.62       109.38         81.43        86.16   
  20            8.86                            107.34      2.03        106.55         86.72        96.79   
  200           4.74                            107.836     5.71        104.9          92.70        87.31   

The extraction efficiencies of tofacitinib and IS exceeded 80% using methanol as the extraction solution, suggesting that it was an ideal precipitation agent. The matrix effect of tofacitinib was between 86.16 and 96.79%. The results demonstrated that the analyte and its internal standard could ignore the influence of matrix effect under the chromatographic and mass spectrometric conditions selected in this experiment.

The stability of tofacitinib was evaluated by analysing the above four conditions, as shown in [Table 2](#t0002){ref-type="table"}. The results indicated that tofacitinib under these conditions was stable in all plasma samples.

###### 

Stability of tofacitinib in plasma samples (*n* = 6).

  Analyte       Stability (% RE)                                    
  ------------- ------------------ ---------- ---------- ---------- ---------
  Tofacitinib   2                  104.12     113.24     112.08     108.14
                80                 113.114    107.894    102.34     110.688
                800                106.8361   105.5872   103.9447   99.8212

Effects of naringenin on the pharmacokinetics of tofacitinib {#s0017}
------------------------------------------------------------

The mean plasma concentration--time curves of tofacitinib in the experimental (preadministered naringenin) and control (equal amounts of vehicle) groups are shown in [Figure 3](#F0003){ref-type="fig"}. The pharmacokinetic parameters are summarized in [Table 3](#t0003){ref-type="table"}.

![The mean plasma concentration--time curves of tofacitinib in the experimental and control groups.](IPHB_A_1738504_F0003_C){#F0003}

###### 

The main pharmacokinetic parameters of tofacitinib in the two groups (*n* = 6, mean ± SD).

  Pharmacokinetics parameters   Experimental group                                Control group
  ----------------------------- ------------------------------------------------- ------------------
  AUC~(0--~*~t~*~)~ (ng/mL/h)   2016.27 ± 481.62[\*](#TF2){ref-type="table-fn"}   1222.81 ± 222.07
  AUC~(0--∞)~ (ng/mL/h)         2198.85 ± 604.38[\*](#TF2){ref-type="table-fn"}   1245.16 ± 201.52
  MRT~(0--~*~t~*~)~ (h)         6.57 ± 0.66[\*](#TF2){ref-type="table-fn"}        4.90 ± 0.51
  MRT~(0--∞)~ (h)               8.71 ± 2.17[\*](#TF2){ref-type="table-fn"}        5.45 ± 1.06
  *t*~1/2~ (h)                  6.30 ± 2.51                                       4.08 ± 1.92
  *T*~max~ (h)                  3.00 ± 0.00[\*](#TF2){ref-type="table-fn"}        0.75 ± 0.29
  Vz (L/kg)                     21.16 ± 8.66                                      25.55 ± 16.08
  CL (L/h/kg)                   2.42 ± 0.70[\*](#TF2){ref-type="table-fn"}        4.10 ± 0.72
  *C*~max~ (ng/mL)              281.84 ± 34.14                                    221.33 ± 54.23

AUC: area under the plasma concentration--time curve; CL: plasma clearance; *C*~max~: maximum plasma concentration; MRT: mean residence time; SD: standard deviation; *t*~1/2~: half-life; *T*~max~: maximum plasma time.

*p* \< 0.05 indicates significant differences from the control.

After oral administration, tofacitinib was rapidly absorbed by the plasma and reached a maximum concentration of 221.33 ± 54.23 ng/mL at 0.75 h. After the rats were preadministered with naringenin (150 mg/kg/day) for 14 days, the AUC~0--24~ of tofacitinib was increased from 1222.81 ± 222.07 to 2016.27 ± 481.62 ng/mL/h, and the difference was significant (*p* \< 0.05). Compared with the control group, the *T*~max~ was increased from 0.75 ± 0.29 to 3.00 ± 0.00 h (*p* \< 0.05), and the MRT~(0--24)~ was increased from 4.90 ± 0.51 to 6.57 ± 0.66 h (*p* \< 0.05), but the clearance (Cl/F) was obviously decreased from 4.10 ± 0.72 to 2.42 ± 0.70 L/h/kg (*p* \< 0.05). Although the *C*~max~ of tofacitinib was increased from 221.33 ± 54.23 to 281.84 ± 34.14 ng/mL, the difference was not significant (*p* \> 0.05). The *t*~1/2~ of tofacitinib in rats pre-treated with naringenin was prolonged compared with the control group (4.08 ± 1.92 vs. 6.30 ± 2.51 h), but the difference was not significant (*p* \> 0.05). These results demonstrated that when the rats were pre-treated with naringenin, the systemic exposure of tofacitinib was significantly increased, and the metabolism was decreased.

Discussion {#s0018}
==========

There are many types of flavonoids, which are widely present in fruits, beverages and herbs in different forms. Therefore, flavonoids and drugs are often coadministered, which may increase the potential of food--drug interactions (Li et al. [@CIT0021]). The interaction between drugs and drugs is generally achieved by the pharmacokinetic properties. Pharmacokinetic interactions between food and drugs may occur in the phase of absorption, distribution, metabolism or excretion. Among them, metabolic drugs have the highest incidence of DDIs (Qiang and Kexin [@CIT0029]; Liu L et al. [@CIT0022]). In addition, the CYP450 system is crucial for drug metabolism. The CYP450 enzymes are involved in the metabolism of endogenous substances (such as fatty acids, vitamins, cholic acid), detoxification of exogenous substances (such as drugs) and activation of precarcinogens (such as aromatic substances). There are more than 50 CYP450 enzymes, most of which are CYP3A4, CYP2C9, CYP2C19, CYP2D6, CYP1A2 CYP2A6 and CYP2E1 enzymes (Chen et al. [@CIT0007]). These enzymes are mainly expressed in the liver, though they are also expressed in the pancreas, brain, lung, adrenal gland, small intestine and bone marrow (Wilkinson [@CIT0038]). Many DDIs are achieved by altering the activity of CYP450 *in vivo* (Zhang et al. [@CIT0042]). At the same time, herbs may also affect CYP450 enzymes, and the flavonoids are among the most important. Hesperetin can affect CYP1A2, and quercetin can affect CYP3A4, CYP2C9, CYP1B1 and CYP1A1 (Chen et al. [@CIT0006]; Pingili et al. [@CIT0028]; Jana and Rastogi [@CIT0017]; Palle and Neerati [@CIT0027]). Naringenin is an aglycone of naringin; it has previously been reported that naringenin can inhibit CYP3A4 (Liu J et al. [@CIT0023]). When drugs metabolized by CYP3A4 enzyme were coadministered with naringenin, the plasma concentrations would be changed which might lead to enhanced clinical adverse effects potentially.

Tofacitinib was absorbed quickly and reached the highest plasma concentration at approximately 45 min after oral administration in this study. It has been reported that the absolute oral bioavailability of tofacitinib was 74% and that the total plasma clearance was 413 mL/min (Gupta et al. [@CIT0014]). The current research indicates that tofacitinib mainly affects CYP3A4 and CYP2C19 (Dowty et al. [@CIT0008]). Some research has shown that when tofacitinib was coadministered with other drugs, such as ketoconazole and fluconazole, their AUC and *C*~max~ values would increase (Gupta et al. [@CIT0015]). In addition, when coadministered with rifampin, the AUC and *C*~max~ of tofacitinib were decreased (Dowty et al. [@CIT0008]). However, there has been little research on DDIs between tofacitinib and traditional Chinese medicine when they are coadministered. Some previous research has found that naringenin can increase the systemic exposure of coadministered drugs (such as ibrutinib, rasagiline and quercetin) (Ni et al. [@CIT0026]; Pingili et al. [@CIT0028]; Liu J et al. [@CIT0023]) by inhibiting CYP3A4-mediated metabolism. Tofacitinib was mainly metabolized by CYP3A4 in the liver; therefore, we speculated that naringenin might increase the plasma concentration of tofacitinib through inhibiting the activity of CYP3A4.

The results indicated that when the rats were pre-treated with naringenin for two weeks, the pharmacokinetics of tofacitinib were significantly changed. Specifically, after oral gavage dosing of tofacitinib in rats, the AUC, MRT and *T*~max~ of it in naringenin preadministered group significantly increased 1.76-, 1.60- and 4.00-fold higher than that of control groups, but the CL/F of tofacitinib decreased by 1.69-fold. Meanwhile, the results showed that the *C*~max~ and *t*~1/2~ of tofacitinib were increased, but there were no significant differences (*p* \> 0.05). In view of the universality and practicability of naringenin, it was important to understand the effects of naringenin on the pharmacokinetics of tofacitinib.

Conclusions {#s0019}
===========

The results of this experiment indicated that naringenin can inhibit the metabolism of tofacitinib in rats. When orally administered, naringenin could increase its AUC, prolong its *t*~1/2~ and decrease its CL. According to several previous studies that proved that naringenin was an inhibitor of CYP3A4, and combined with the results of our experiments, we could conclude that naringenin affects the metabolism of tofacitinib by inhibiting the action of CYP3A4; however, the specific mechanism of action requires further verification. Therefore, when taking tofacitinib for rheumatoid arthritis, people should pay attention to the intake of food or herbs containing naringenin, and the dose of tofacitinib might be adjusted.
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